Albumin Market Size, Share, Trends & Forecast
The Albumin Market is expanding as healthcare providers and pharmaceutical companies increase their use of albumin across therapeutic, diagnostic, and biopharmaceutical applications. The market was valued at USD 1.01 billion in 2024 and is projected to reach USD 1.89 billion by 2035, registering a 5.92% CAGR from 2025 to 2035.
Therapeutic applications currently represent the largest application segment because albumin is widely used in critical-care settings and treatments associated with liver disorders, burns, and shock. Diagnostic applications are emerging rapidly as laboratory technologies advance and demand for accurate testing continues to increase.
Pharmaceutical companies remain the leading end users, supported by albumin's role in drug formulations and therapeutic products. Biotechnology is becoming a faster-growing area as biopharmaceutical developers use albumin in advanced formulations and research involving biologics and personalized medicine.
Human plasma remains the dominant source because of its established clinical use and compatibility with patients. Recombinant albumin is gaining attention as biotechnology advances offer an alternative that can address supply, safety, and ethical considerations associated with blood-derived products.
North America leads the global market, with demand supported by therapeutic protein use, biotechnology investment, and established healthcare infrastructure. Asia-Pacific is expected to provide strong future opportunities as healthcare systems and biopharmaceutical manufacturing expand, while sustainable production and improved purification technologies continue to reshape the industry.
Explore key developments shaping industry transformation:
Veterinary Medicine Market Volume
Veterinary Medicine Market Forecast
Veterinary Medicine Market Outlook